Search results for "mucositis"

showing 10 items of 103 documents

Oral necrotizing microvasculitis in a patient affected by Kawasaki disease

2007

Kawasaki disease (KD) was first described in 1967 by Kawasaki, who defined it as ?mucocutaneous lymph node syndrome?. KD is an acute systemic vasculitis, which mainly involves medium calibre arteries; its origin is unknown, and it is observed in children under the age of 5, especially in their third year. The principal presentations of KD include fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in the extremities, rash, and cervical lymphadenopathy. Within KD, oral mucositis ? represented by diffuse mucous membrane erythema, lip and tongue reddening and lingual papillae hypertrophy with subsequent development of strawberry tongue ? can occur both i…

Kawasaki diseaseORAL NECROTIZING MICROVASCULITISUNESCO::CIENCIAS MÉDICAS:CIENCIAS MÉDICAS [UNESCO]ORAL NECROTIZING MICROVASCULITIS;KAWASAKI DISEASEvasculitisKAWASAKI DISEASEoral mucositis
researchProduct

Carbon ions and X‑rays induce pro‑inflammatory effects in 3D oral mucosa models with and without PBMCs.

2014

Oral mucositis is a severe complication of radiotherapy. Hence, it may constitute a serious medical safety risk for astronauts during extended space flights, such as missions to Mars, during which they are exposed to heavy-ion irradiation. For risk assessment of developing radiation-induced mucositis, a three-dimensional (3D) organotypic oral mucosa model was irradiated with 12C heavy ions or X‑rays. The present study focused mainly on early radiation‑induced effects, such as the activation of nuclear factor κB (NFκB) and the expression or release of pro-inflammatory marker molecules. The 3D oral mucosa models with or without peripheral blood mononuclear cells (PBMCs) were irradiated with X…

KeratinocytesCancer ResearchDNA damageBiologyPeripheral blood mononuclear cellModels BiologicalmedicineMucositisHumansHeavy IonsInterleukin 8Oral mucosaCells CulturedX-RaysMouth MucosaInterleukinGeneral Medicinemedicine.diseaseCarbonCoculture TechniquesOrganoidsmedicine.anatomical_structureOncologyApoptosisToxicityCancer researchLeukocytes MononuclearCytokinesDNA DamageOncology reports
researchProduct

Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model

2015

Background and Aims Intestinal mucositis is a frequently encountered side effect in oncology patients undergoing chemotherapy. No well-established or up to date therapeutic strategies are available. To study a novel way to alleviate mucositis, we investigate the effects and safety of probiotic supplementation in ameliorating 5-FU-induced intestinal mucositis in a mouse model. Methods Seventy-two mice were injected saline or 5-Fluorouracil (5-FU) intraperitoneally daily. Mice were either orally administrated daily saline, probiotic suspension of Lactobacillus casei variety rhamnosus (Lcr35) or Lactobacillus acidophilus and Bifidobacterium bifidum (LaBi). Diarrhea score, pro-inflammatory cyto…

Lactobacillus caseimedicine.medical_specialtyved/biology.organism_classification_rank.specieslcsh:MedicineGastroenterologylaw.inventionProbioticLactobacillus acidophilusIntestinal mucosalawInternal medicinemedicineMucositislcsh:ScienceBifidobacteriumMultidisciplinaryBifidobacterium bifidumbiologyved/biologybusiness.industrylcsh:RIntestinal villusfood and beveragesmedicine.diseasebiology.organism_classificationmedicine.anatomical_structureImmunologylcsh:QbusinessResearch ArticlePLOS ONE
researchProduct

The effect of orally administered probiotic Lactobacillus reuteri -containing tablets in peri-implant mucositis: a double-blind randomized controlled…

2015

Background and Objectives Probiotics create a biofilm and protect the oral tissues against the action of periodontal pathogenic bacteria. The aim of this study was to evaluate the effects of the oral probiotic Lactobacillus reuteri Prodentis upon the peri-implant health of edentulous patients with dental implants and peri-implant mucositis, establishing comparisons vs implants without peri-implant disease. Material and Methods A double-blind, placebo-controlled, prospective cross-over study was made. The patients were all edentulous and were divided into two groups, (A) no peri-implant disease, and (B) peri-implant mucositis affecting one or more implants. Patients with peri-implantitis wer…

Limosilactobacillus reuteriMaleMucositismedicine.medical_specialtyPeri-implant mucositisDentistryPlaceboGastroenterologylaw.inventionPlacebosProbioticDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineMucositisHumansProspective StudiesProspective cohort studyAgedCross-Over Studiesbiologybusiness.industryProbioticsMiddle Agedmedicine.diseasebiology.organism_classificationCrossover studyLactobacillus reuteriDental ImplantationTreatment OutcomeCytokinesPeriodonticsFemalebusinessTabletsJournal of Periodontal Research
researchProduct

Melatonin protects rats from radiotherapy-induced small intestine toxicity

2017

Radiotherapy-induced gut toxicity is among the most prevalent dose-limiting toxicities following radiotherapy. Prevention of radiation enteropathy requires protection of the small intestine. However, despite the prevalence and burden of this pathology, there are currently no effective treatments for radiotherapy-induced gut toxicity, and this pathology remains unclear. The present study aimed to investigate the changes induced in the rat small intestine after external irradiation of the tongue, and to explore the potential radio-protective effects of melatonin gel. Male Wistar rats were subjected to irradiation of their tongues with an X-Ray YXLON Y.Tu 320-D03 irradiator, receiving a dose o…

Male0301 basic medicineCancer TreatmentDrug Evaluation Preclinicallcsh:MedicineExpressionApoptosisToxicologyPathology and Laboratory Medicinemedicine.disease_causeBiochemistryOxidative Phosphorylation0302 clinical medicineIntestinal mucosaGastrointestinal tractIntestine SmallMedicine and Health SciencesRadiation-injuryIntestinal Mucosalcsh:ScienceEnergy-Producing OrganellesMelatoninCancerMultidisciplinaryNF-kappa BInflammasomeLipid-peroxidationGlutathioneMitochondriaRadiation therapyRadiation Injuries Experimentalmedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer treatmentToxicityInflammasome activationSmall IntestineExperimental pathologyAnatomyCellular Structures and OrganellesResearch Articlemedicine.drugClinical OncologyMucositismedicine.medical_specialtyRadiation TherapyRadiation-Protective AgentsBioenergeticsBiologyRadiation enteropathyMelatonin03 medical and health sciencesTongueInternal medicineSepsisNLR Family Pyrin Domain-Containing 3 ProteinmedicineAnimalsRats WistarMouthToxicitylcsh:RBiology and Life SciencesCell BiologySmall intestinemedicine.diseaseHormonesSmall intestinePathobiologyGastrointestinal TractOxidative Stress030104 developmental biologyEndocrinologylcsh:QClinical MedicineDigestive SystemGelsOxidative stress
researchProduct

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

2017

Cytarabine is considered the most effective chemotherapeutic option in acute myeloid leukemia (AML). The impact of 10 polymorphisms in cytarabine metabolic pathway genes were evaluated in 225 adult de novo AML patients. Variant alleles of DCK rs2306744 and CDA rs602950 showed higher complete remission (p = .024, p = .045), with lower survival rates for variant alleles of CDA rs2072671 (p = .015, p = .045, p = .032), rs3215400 (p = .033) and wild-type genotype of rs602950 (p = .039, .014). Induction death (p = .033) and lower survival rates (p = .021, p = .047) were correlated to RRM1 rs9937 variant allele. In addition, variant alleles of CDA rs532545 and rs602950 were related to skin toxici…

Male0301 basic medicineOncologyCancer ResearchPharmacogenomic VariantsefficacyKaplan-Meier Estimatepolymorphism0302 clinical medicinePolymorphism (computer science)GenotypeRemission InductionCytarabineDCKMyeloid leukemiaHematologyMiddle AgedPrognosisLeukemia Myeloid AcuteOncology030220 oncology & carcinogenesisToxicityFemaleMetabolic Networks and Pathwaysmedicine.drugAdultAntimetabolites Antineoplasticmedicine.medical_specialtyAdolescentGenotypeacute myeloid leukemiaPolymorphism Single NucleotideYoung Adult03 medical and health sciencesInternal medicinemedicineMucositisHumansAlleleAllelesAgedRetrospective StudiesPolymorphism Geneticbusiness.industrymedicine.diseaseMinor allele frequency030104 developmental biologyCDAImmunologyCytarabinebusiness
researchProduct

Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic th…

2017

// Gemma Bruera 1, 2 , Antonio Russo 3 , Antonio Galvano 3 , Sergio Rizzo 3 and Enrico Ricevuto 1, 2 1 Oncology Territorial Care, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy 2 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy 3 Medical Oncology, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy Correspondence to: Antonio Russo, email: antonio.russo@usa.net Keywords: elderly, intensive treatment, metastatic colorectal cancer, triplet chemotherapy plus bevacizumab, unfit Received: June 07, 2016     Accepted: November 24, 2016     Published:…

Male0301 basic medicineUnfitmedicine.medical_specialtyBevacizumabColorectal cancerDecision MakingAngiogenesis InhibitorsNeutropeniamedicine.disease_cause03 medical and health sciences0302 clinical medicineElderlyInternal medicinemedicineMucositisHumansNeoplasm MetastasisAgedRetrospective StudiesTriplet chemotherapy plus bevacizumabbusiness.industryMetastatic colorectal cancerelderly; intensive treatment; metastatic colorectal cancer; triplet chemotherapy plus bevacizumab; unfitRetrospective cohort studymedicine.diseaseComorbiditySurgeryRegimenTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleIntensive treatmentKRASClinical Research PaperColorectal NeoplasmsbusinessElderly; Intensive treatment; Metastatic colorectal cancer; Triplet chemotherapy plus bevacizumab; Unfit; Oncologymedicine.drug
researchProduct

Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

2015

In this phase I/II study, we explored the combination of Temsirolimus with Bendamustine and Rituximab (BeRT) in patients with r/r follicular lymphoma (FL) or mantle cell lymphoma (MCL). Patients with 1-3 prior therapies received Bendamustine (90 mg/m(2), day 1+2) and Rituximab (375 mg/m(2), day 1) with Temsirolimus in doses from 25 to 75 mg added on day 1, 8, 15 of a 28-day cycle. Fifteen (11 MCL, 4 FL) patients were included in the phase I. Median age was 73 years and median pretreatment number was 2. No formal dose-limiting toxicity was observed. Dominant non-hematological side effects were fatigue in 11 (73%), nausea in 9 (60%), mucositis in 7 (47%) and vomiting in 6 patients (40%). Coug…

MaleBendamustineCancer Researchmedicine.medical_specialtyMaximum Tolerated DoseFollicular lymphomaLymphoma Mantle-CellNeutropeniaGastroenterologyAntibodies Monoclonal Murine-Derivedhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisBendamustine HydrochlorideHumansProspective StudiesLymphoma FollicularAgedNeoplasm StagingSirolimusLeukopeniabusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseTemsirolimusSurgerySurvival RateOncologyNitrogen Mustard CompoundsFeasibility StudiesFemaleMantle cell lymphomaRituximabNeoplasm Recurrence LocalSafetymedicine.symptomRituximabbusinessFollow-Up Studiesmedicine.drugLeukemia
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Single-blind randomized clinical trial to evaluate clinical and radiological outcomes after one year of immediate versus delayed implant placement su…

2013

Purpose: To evaluate and compare peri-implant health, marginal bone loss and success of immediate and delayed implant placement for rehabilitation with full-arch fixed prostheses. Material and Methods: The present study was a prospective, randomized, single-blind, clinical preliminary trial. Patients were randomized into two treatment groups. In Group A implants were placed immediately post-extraction and in Group B six months after extraction. The following control time-points were established: one week, six months and twelve months after loading. Measurements were taken of peri-implant crevicular fluid volume, plaque index, gingival retraction, keratinized mucosa, probing depth, modified …

MaleImmediate Dental Implant LoadingTime FactorsRadiographyDentistryImmediate implantsProsthesis Designlaw.inventionRandomized controlled triallawperi-implant healthMucositisMedicineHumansSingle-Blind MethodProspective Studiessuccess rateProspective cohort studyGeneral Dentistrybusiness.industryResearchImmediate implants delayed implants peri-implant health success rateDental prosthesisMiddle Agedmedicine.diseaseImplant placementRadiographyDental ImplantationTreatment OutcomeOtorhinolaryngologyJawRadiological weaponSurgeryFemaleImplantDental Prosthesis Implant-Supporteddelayed implantsbusinessImplantology
researchProduct